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INTRODUCTION
Uterine cervical cancer is the most common malignancy
of the female genital tract, and in 2002 accounted for 9.1%
of total malignancies in Korean women (1). Neoadjuvant
chemotherapy (NAC) based on cisplatin has been widely used
as a therapeutic strategy to improve survival in locally ad-
vanced cervical cancer (2-4). Of the several available NAC
regimens, a quick (at most three cycles) course of vincristine,
bleomycin, and cisplatin is to be preferred due to short dura-
tion. NAC administered every 10 days has been tried and
found to produce favorable results (5, 6). Furthermore, bleo-
mycin-induced pulmonary toxicity, one of the most fatal ad-
verse effects, has been reported to be unusual after a quick
course of NAC-VBP (5-7). However, we have experienced
several fatal cases of pulmonary toxicity, at levels higher than
those reported in the literature (5-10), associated with a quick
course of NAC-VBP in patients with International Federa-
tion of Gynecology and Obstetrics (FIGO) stage IB-IIB cer-
vical cancer. 
In the present study, we analyzed our experiences of radi-
ologically and/or histologically confirmed pulmonary toxic-
ity following a quick course of NAC-VBP in cervical cancer.
MATERIALS AND METHODS
After obtaining the approval of the Institutional Review
Board of Kyung Hee University (Seoul), 61 patients who
underwent a quick course of NAC-VBP in FIGO stage IB-
IIB cervical cancer from 1995 to 2007 were retrospectively
identified in the tumor registry databases at the Department
of Obstetrics and Gynecology. The NAC schedule consisted
of cisplatin 50 mg/m2intravenous infusion on day 1, vincristine
1 mg/m2 intravenous bolus on day 1, and bleomycin 25 mg/
m2/day continuous intravenous infusion on days 1 to 3. Cycles
were repeated every 10 days for a maximum of three cycles.
Patients were hospitalized for each chemotherapy period. Prior
to administering chemotherapy, complete medical assessments,
including chest radiography, creatinine clearance, renal func-
tion, and pulmonary function testing (PFT), were performed.
Toxicities were measured using WHO criteria (11). Inten-
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Pulmonary Toxicity after a Quick Course of Combinatorial Vincristine,
Bleomycin, and Cisplatin Neoadjuvant Chemotherapy in Cervical Cancer
Pulmonary toxicity is one of the most serious adverse effects associated with a quick
course of vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy (NAC-
VBP). The aim of this study was to evaluate pulmonary toxicity related to a quick
course NAC-VBP. A total of consecutive 61 patients, who underwent at most 3 cycles
of NAC-VBP every 10 days in the International Federation of Gynecology and Obstet-
rics (FIGO) stage IB-IIB cervical cancer from 1995 to 2007, were retrospectively
analyzed. Of the 61 study subjects, 7 (11.5%) were identified to have pulmonary
toxicity and 2 (3.3%) died of pulmonary fibrosis progression despite aggressive treat-
ment and the use of a multidisciplinary approach. No factor predisposing pulmonary
toxicity was identified. Initial symptoms were non-specific, but bronchiolitis obliter-
ans organizing pneumonia and interstitial pneumonitis were characteristic findings
by high-resolution computed tomography of the chest. The benefit of steroid thera-
py was uncertain and was associated with steroid-induced diabetes mellitus requir-
ing insulin therapy in two patients. Fatal pulmonary toxicity is a major concern of a
quick course NAC-VBP. In conclusion, these patients require special monitoring for
bleomycin-induced pulmonary toxicity.
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sive work ups, such as, high-resolution computed tomogra-
phy (HR-CT) with or without bronchoscopic biopsy, were
performed in all cases with pulmonary symptoms or suspi-
cious findings by chest radiography during or after NAC-
VBP. Histopathologic slides were reviewed by pathologists
at our institute with considerable experience of gynecologic
malignancies and pulmonary disease.
RESULTS
A total of 61 patients underwent a quick course of NAC-
VBP. No patient had a history of thoracic radiation therapy.
Seven (11.5%) of the 61 patients were identified to have pul-
monary toxicity and 2 (3.3%) succumbed due to progression
of pulmonary fibrosis despite aggressive treatment and the
adoption of a multidisciplinary approach. 
A comparison of the demographic factors of patients with
and without pulmonary toxicity identified no significant dif-
ferences in terms of age, parity, histologic type, or total bleo-
mycin dose (Table 1). 
The histories of 7 patients with pulmonary toxicity are
briefly summarized in Table 2. All 7 patients had normal
renal and pulmonary functions before NAC-VBP. Pulmonary
toxicity was first suspected based on clinical symptoms or
routine chest-radiographic and/or pulmonary function test
findings, and was subsequently confirmed by HR-CT with
or without a bronchoscopic biopsy. Three patients were com-
pletely asymptomatic in terms of respiratory symptoms but
had suspicious chest radiographic findings. Of the 4 symp-
tomatic patients, 1 suffered from a fever and sputum produc-
tion, and 3 complained of pulmonary symptoms such as dys-
pnea and/or cough. Two of the 3 asymptomatic patients were
closely observed and spontaneously improved, but 1 patient
deteriorated gradually and eventually found it hard to breathe.
She was treated with medication containing corticosteroid
(prednisolone 1 mg/kg/day). However, her symptom persist-
ed, and thus, corticosteroid was continued at a reduced dose
(prednisolone 0.5 mg/kg/day). One patient with fever and
sputum production improved on conservative management.
In the 3 patients who complained of dyspnea and pulmonary
symptoms, 1 improved on steroid therapy (methylpredniso-
lone 40 mg/day, followed by maintenance therapy methyl-
prednisolone 10 mg/day). However, the other 2 patients dete-
riorated and pulmonary fibrosis progression despite steroid
pulse therapy (methylprednisolone 500 mg/day for 3 days)
and developed acute respiratory distress syndrome, which
led to respiratory arrest and death in both within 1 month
of diagnosing pulmonary toxicity. In these two patients, bron-
chiolitis obliterans organizing pneumonia (BOOP) or inter-
stitial pneumonitis were characteristic chest HR-CT findings.
These findings of BOOP were characterized by multifocal,
patchy distributions of ground glass attenuation and consol-
Variables
No pulmonary 
toxicity 
(n=54)
Pulmonary 
toxicity 
(n=7)
P
value
Age, yr (%) 0.615
≤65 44  (81.5) 5  (71.4)
>65 10  (18.5) 2  (28.6)
Parity (%) 1.000
≤3 38 (70.4) 5 (71.4)
>3 16 (29.6) 2 (28.6)
Histology (%) 0.525
Squamous cell carcinoma 46 (85.2) 6 (85.7)
Adenocarcinoma 7  (13.0) 0
Adenosquamous carcinoma 1 (1.9) 1 (14.3)
Stage (%) 0.394
IB-IIA 51 (94.4) 6 (85.7)
IIB 3 (5.6) 1 (14.3)
Total dose of bleomycin (%) 0.643
≤350 mg 43 (79.6) 5 (71.4)
>350 mg 11 (20.4) 2 (28.6)
Table 1. Patients characteristics
NAC, Neoadjuvant chemotherapy; Asx, Asymptomatic; BOOP, Bronchiolitis obliterans organizing pneumonia; HR-CT, high-resolution computed tomog-
raphy.
Case
Age
(yr)
Stage
Histologic
type
Initial
symptom
Imaging
findings
Diagnostic
methods
Interval
from NAC
(month)
Management Outcome
1 48 IB2 Squamous Asx BOOP HR-CT 2 Conservative Improved
2 50 IIA Squamous Dyspnea Intersitial pneumonitis HR-CT, Biopsy 5 Steroid therapy Improved
3 62 IIB Squamous Fever, sputum Bronchiectasis, HR-CT 2 Conservative Improved
R/O BOOP
4 65 IIA Squamous Asx Intersitial pneumonitis HR-CT 4 Conservative Improved
5 69 IIA Squamous Asx Intersitial pneumonitis HR-CT, Biopsy 2 Steroid therapy Persistent
6 56 IB2 Adeno- Cough,  BOOP HR-CT, Biopsy 1 Steroid therapy and  Expired
squamous dyspnea immune suppressive agents
7 68 IIA Squamous Dyspnea Intersitial pneumonitis HR-CT 1 Steroid therapy Expired
Table 2. Analysis of 7 cases that developed pulmonary toxicity after a quick course of vincristine, bleomycin, plus cisplatin neoadju-
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idation, predominantly in the subpleural region, with partial
bronchovascular bundle thickening and interlobular septal
thickening by HR-CT (Fig. 1). The presence of interstitial
pneumonitis was demonstrated by diffuse extensive homoge-
nous ground glass attenuation, which was more prominent
in the subpleural region, intermixed with interlobular sep-
tal thickenings, bronchiectasis, and honeycomb cysts. These
findings suggested diffuse alveolar damage or acute phases
interstitial lung disease, such as, nonspecific interstitial pneu-
monia (Fig. 2). Alveolar damage was confirmed by broncho-
scopic biopsies (Fig. 3). Furthermore, as a result of long term
steroid use, steroid-induced diabetes mellitus requiring insulin
therapy developed in two patients (cases 2 and 5).
DISCUSSION
It remains unclear whether NAC improves survival out-
comes as compared with primary radical surgery or concur-
rent chemoradiation therapy in cervical cancer (7, 9, 12-14).
Nevertheless, many gynecologic oncologists perform NAC
to reduce tumor volume and consequently to improve sur-
vival, based on clinician’s preference and the medical resources
available, and thus, the usefulness of NAC is probably beyond
the scope of this study. Rather, we focus on pulmonary toxi-
city, one of the most fatal adverse effects following a quick
course of NAC-VBP.
Pulmonary toxicity exacerbation by combination chemo-
therapy has already been reported upon (15), and of several
chemotherapeutic agents responsible, bleomycin has been
identified as the most causative agent (16). Pulmonary toxi-
city is the most fatal adverse effect of bleomycin, and may
occur in up to 46% of patients (17, 18), with a mortality rate,
among those treated, of approximately 3% (19, 20). Howev-
er, pulmonary toxicity is rare after a quick NAC-VBP course,
which is one of the most popular NAC regimens used in cer-
vical cancer (6-10, 21, 22). Table 3 itemizes publications on
pulmonary toxicity after a quick course of NAC-VBP in cervi-
cal cancer. The majority of series reported pulmonary toxicity
in only 0-2% of the population studied, and that it occurred
more frequently in elderly patients (5, 21). However, another
study reported that a quick course of NAC-VBP in cervical
cancer was associated with significant pulmonary toxicity in
13.3% of cases (22), which is similar to the present study.
These findings stress that the possibility of pulmonary toxi-
city should be considered in patients receiving a quick course
Fig. 1. Case 6, Chest HR-CT of 1 week after surgery revealing bron-
chiolitis obliterans organizing pneumonia.
Fig. 2. Case 7, Chest HR-CT of 2 month after surgery revealing
diffuse alveolar damage with underlying interstitial lung disease.
Fig. 3. Case 2, Photomicrograph revealing interstitial widening with
chronic inflammatory cell infiltration and foci of intraalveolar fibrob-
lastic plugs (H&E stain, ×100), Lung biopsy.Pulmonary Toxicity related to Quick NAC in Cervical Cancer 243
of NAC-VBP. 
Bleomycin is available in two forms, i.e., as a sulfate and
chlorohydrate. In the present study, we used bleomycin chloro-
hydrate which causes less pulmonary toxicity (5, 21). How-
ever, the mechanisms of bleomycin-induced pulmonary tox-
icity are not entirely understood, though several factors, includ-
ing old age (>70 yr), a high cumulative dose, impaired renal
function, administration route, smoking, granulocyte colony
stimulating factor (G-CSF) use, and multiple chemotherapeu-
tics agents (mainly cisplatin) may increase its risk (17). In the
present study, all patients with pulmonary toxicity were non-
smokers and were confirmed to have normal renal function by
creatinine clearance before each chemotherapy cycle. In addi-
tion, we found no evidence that age and cumulative bleo-
mycin dose were significantly different for patients with/with-
out pulmonary toxicity, and thus, we failed to identify any
factor predisposing pulmonary toxicity. 
Bleomycin-induced pulmonary toxicity may be reversible
in cases with minimal alveolar change, but in its advanced
state may progress to severe fibrosis and death (23). More-
over, although high doses of corticosteroids have been wide-
ly administered in cases of bleomycin-induced pulmonary
toxicity, no standard therapy has been agreed. In addition,
the efficacies of corticosteroids are unclear and the adverse
effects of long term corticosteroid therapy, such as, steroid-
induced diabetes mellitus may be grave (18).
We conclude fatal pulmonary toxicity is a major concern
of quick NAC-VBP regimens, and advise that special atten-
tion be taken to monitor for bleomycin-induced pulmonary
toxicity.
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